| A Pharmacokinetic Study of D-2570 in Participants With Hepatic Impairment and Normal Hepatic Function (NCT07715149) | InventisBio Co., Ltd | 2026-07-14 |
| Study of D-2570 in Subjects With Non-Segmental Vitiligo (NCT07625891) | InventisBio Co., Ltd | 2026-06-11 |
| A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis (NCT07489885) | InventisBio Co., Ltd | 2026-06-03 |
| Mass Balance Study of [14C] D-2570 (NCT07411742) | InventisBio Co., Ltd | 2026-03-10 |
| A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE) (NCT07311200) | InventisBio Co., Ltd | 2026-02-12 |
| A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis (NCT07315061) | InventisBio Co., Ltd | 2026-01-16 |
| A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis (NCT07326813) | InventisBio Co., Ltd | 2026-01-12 |
| Healthy Volunteer Study (NCT07270783) | InventisBio Co., Ltd | 2025-12-04 |
| Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis (NCT07130604) | InventisBio Co., Ltd | 2025-09-18 |
| A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis (NCT07035041) | InventisBio Co., Ltd | 2025-05-22 |
| Single and Multiple Dose and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-2570 Tablets in Healthy Subjects (NCT07275775) | InventisBio Co., Ltd | 2024-08-13 |
| Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis (NCT06278350) | InventisBio Co., Ltd | 2024-01-31 |
| Mass Balance Study of [14C] D-1553 in Chinese Healthy Adult Male Subjects (NCT06233916) | InventisBio Co., Ltd | 2023-12-08 |
| A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553 (NCT06105255) | InventisBio Co., Ltd | 2023-05-24 |
| Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout (NCT05665699) | InventisBio Co., Ltd | 2023-04-17 |
| Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors (NCT05379946) | InventisBio Co., Ltd | 2022-10-12 |
| Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients (NCT05504083) | InventisBio Co., Ltd | 2022-09-28 |
| A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer (NCT06954961) | InventisBio Co., Ltd | 2022-09-15 |
| Study in Healthy Adult Female Subjects (NCT05339633) | InventisBio Co., Ltd | 2022-03-29 |
| Evaluation of PK and Safety of D-0120 and Allopurinol (NCT05360628) | InventisBio Co., Ltd | 2021-11-01 |
| Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female Subjects (NCT05226338) | InventisBio Co., Ltd | 2021-10-27 |
| Study to Evaluate D-1553 in Subjects With Solid Tumors (NCT04585035) | InventisBio Co., Ltd | 2020-10-02 |
| Phase I Study of D-0120 to Evaluate Safety and PK/PD Study in Healthy Volunteers (NCT04097405) | InventisBio Co., Ltd | 2019-09-18 |
| D-0120 Safety and PK/PD Study in China (NCT03923868) | InventisBio Co., Ltd | 2019-04-18 |
| D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer (NCT03861156) | InventisBio Co., Ltd | 2019-02-28 |
| Food Effect Study of D-0502 Tablet in Healthy Volunteers (NCT03810625) | InventisBio Co., Ltd | 2018-10-23 |
| A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer (NCT03471663) | InventisBio Co., Ltd | 2018-03-18 |
| D-0316 First Time in Patients Ascending Dose Study (NCT03452150) | InventisBio Co., Ltd | 2018-01-03 |
| D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers (NCT03291782) | InventisBio Co., Ltd | 2017-09-13 |